# Silo Pharma, Inc. (SILO) · Edgar & Edgarette company card

> Silo Pharma (SILO) grew revenue 0.0% in FY2025 to $0 million, operating margin -5937% against a -3.8% median for pharmaceutical preparations, equity 82.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1514183 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/SILO) · [JSON](https://www.pops4.com/boards/company/SILO.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $72,102 |
| Revenue growth, 1 year | 0.0% |
| Revenue growth per year | 12.0% |
| Operating margin | -5937.0% (prior year -6526.4%) |
| Net margin | -5863.5% |
| Operating cash flow | −$5M |
| Capital spending | — |
| Free cash flow | — |
| Cash | $5M |
| Long-term debt | — |
| Total assets | $8M |
| Total equity | $6M |
| Equity ÷ assets | 82.9% |
| Return on equity | -67.0% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -1.23 (distress zone)
- Piotroski F: 3 of 9 (middling)
- Health Harbor boat: Old boat · three warning signs · operating cash flow was negative (-$4.7M in FY2025); operating loss: a margin of -5937.0% in FY2025; revenue is hard to predict: its 80% range is ±43%

## Edgarette's reading

Exposure: revenue $72K (FY2025). Experience: revenue up 0.0% on the year, up 12.0% a year over 5 years; operating margin -5937.0%, up from -6526.4%. Soundness: equity 82.9% of assets, return on equity -67.0%. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $45K and $111K next year (method v4.1: its own 3-year record of growth weighed at 40% against under $50M filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $42K to $119K. A statistical range, not company guidance. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin -5937.0% against a -3.8% median; growth 0.0% against 13.7%.

Range logged 2026-10-05, receipt 59f656b2663818a8, status open. A statistical range, not company guidance.

## Health Watch, last 12 months

- Item 3.01 Exchange listing notice or transfer: 1, latest 2025-12-29 ([filing](https://www.sec.gov/Archives/edgar/data/1514183/000121390025125838/0001213900-25-125838-index.htm))

## Recent filings

- 10-Q · filed 2026-11-13 · [filing](https://www.sec.gov/Archives/edgar/data/1514183/000121390026119792/0001213900-26-119792-index.htm)
- 8-K · filed 2026-11-06 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1514183/000121390026116982/0001213900-26-116982-index.htm)
- 8-K · filed 2026-10-14 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1514183/000121390026109457/0001213900-26-109457-index.htm)
- 8-K · filed 2026-10-02 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1514183/000121390026106435/0001213900-26-106435-index.htm)
- 8-K · filed 2026-08-19 · 1.01 Entry into a Material Definitive Agreement; 3.02 Unregistered Sales of Equity Securities; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1514183/000121390026091783/0001213900-26-091783-index.htm)
- 8-K · filed 2026-08-17 · 5.03 Amendments to Articles or Bylaws; Change in Fiscal Year; 5.07 Submission of Matters to a Vote of Security Holders; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1514183/000121390026090748/0001213900-26-090748-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001514183.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1514183

## Cite

POPS4, Edgar & Edgarette: Silo Pharma, Inc. (SILO) company card, from the company's own SEC filings, accessed 2026-11-19, https://www.pops4.com/boards/company/SILO. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.

